

## CV Linos Vandekerckhove

Orcid ID:[orcid.org/0000-0002-8600-1631](https://orcid.org/0000-0002-8600-1631), Research ID: J-6420-2013, Born: 09/10/1973 Oostende, Belgium. URL for web site: [www.HIV-1ontrafelen.be](http://www.HIV-1ontrafelen.be), Linos.vandekerckhove@ugent.be

### Education and training:

2010: 4 months **visiting professor with focus on HIV-1 cure**: Gladstone Institute, University of San Francisco, US.

2002-2006: **PhD in molecular virology**, Rega Institute, Faculty of Medical Sciences, Catholic University Leuven, Belgium. This PhD was successfully defended 22 September 2006.

2001-2001: **training Internal Medicine Specialist, Pretoria Academic Hospital**, South Africa.

1999-2006: **training Internal Medicine Specialist**, Faculty of Medical Sciences, Catholic University Leuven, Belgium .

1998-1999: Specialist in **Tropical Medicine**, Institute of Tropical Medicine, Antwerp, Belgium.

1991-1998:**MD- distinction, Faculty of Medical Sciences**, Catholic University Leuven, Belgium

**Current positions:** 2010 – Current Position: **Head HIV-1 Cure Research Centre**, Faculty of Medicine and Health Sciences, University Ghent, Belgium. 2010 – Current Position: **Assistant professor in Internal Medicine** (5%), Faculty of Medicine and Health Sciences, University Ghent, Belgium. 2009 – Current Position: Head of Clinic in Internal Medicine, **Coordinator HIV-1 Clinical unit**, Principal Investigator HIV-1 clinical trials, Ghent University Hospital, Belgium (100%).

### Fellowships and awards

2003 – 2006: **PhD fellowship** from the agency for Innovation by Science and Technology Flanders, executed at the Rega Institute, Faculty of Medical Sciences, Catholic University Leuven, Belgium.

2008-2018: Fund for Scientific Research Flanders, **postdoctoral Fundamental Clinical Mandate**, University Hospital Ghent, Belgium. 2005: **Young Investigator Award** at the Annual Congress of the Belgian Society of Internal Medicine from the Belgian Society of Internal Medicine, Belgium.

2006: **Young Investigator Award**; February 2006: Conference on Retroviruses and Opportunistic infections, Denver, US. 2006: **Young Investigator Award** for Basic HIV-1 research; (1 out of 13000 submitted abstracts); August 2006: XVI World Aids Conference, Toronto, Canada.

2014: **Award for best basic research** “analysis of the viral reservoir in distinct patient cohorts”. Belgian HIV-1 annual congress.

### Supervision of graduate students and postdoctoral fellows:

2008-2017: Supervision of PhD students that defended their PhD: **Peter Messiaen, Maja Kiselinova, Pawel Bosckowski and Eva Malatinkova**

2011- 2016: **post- doc supervision Ward De Spiegelaere**(now faculty member, Veterinarian Medicine).

2016- Still ongoing: **post- doc supervision Eva Malatinkova, Magdalena Sips and recently Wojciech Witkowski**

2012- Still ongoing: **supervision of 8PhD students**, Faculty of Medicine and Health Sciences, University Hospital Ghent

### Teaching activities:

2009 – ongoing: “Critical reflections on clinical practice in infectious diseases”(4h), 3e master in Medicine, University Ghent, Belgium (45 students).

2009-ongoing: “**General Medical Pathology**”: The patient with glands due to **viral infections**”(4h), 2e master in Dentistry, University Ghent, Belgium (30 students).

2009-ongoing: “**Capita Selecta**” (4h)in Master after Master for the Hospital doctor and for the second year Registrar, University Ghent, Belgium (120 Students).

**Coordinating Examiner** for the integrated clinical examination for students of the 4e master in Medicine (8h/y) (8students). Examiner master thesis in medicine (8h/y) (4students)

2014-ongoing: **organizer** of the annual HIV reservoir quantification course (3 day program, 30 students, International educational course).

2014-ongoing: **Manama in Internal Medicine** 4h/week: 200h/year  
2017-ongoing: **HIV specialist nurse training** 1h/month: 12h/year  
2015-ongoing: **Post graduate training of General Practitioner**: 10x 2h sessions: 20h/year

**Organization of Scientific Meetings:** 2008: **Symposium organizer**: Belgian HIV-1 reference center and laboratory day, Ghent, Belgium, 170 participants.

2013- ongoing: **scientific committee member**: European HIV-1 & Hepatitis Workshop , annually 300 participants.

2013- ongoing: **scientific committee member**: **European aids conference**, 5500 participants.

2015- ongoing: **scientific committee member**: **European conference on Clinical Microbiology and Infectious Diseases** (>10.000 attendees)

2016- ongoing: **scientific committee member**: **Belgian HIV Research Day (BREACH)**

2017- ongoing: organizer HIV Cure meeting (200 attendees).

### **Institutional Responsibilities**

2009-ongoing: **member of the department of Internal medicine**, University Ghent, Ghent, Belgium.

2006-ongoing: steering member of the Council for antibiotic stewardship, University Hospital Ghent, Ghent, Belgium.

2009-ongoing: **Principal Investigator EuroSIDA** (150 study participants)(EuroSIDA study is a prospective observational cohort study of more than 25.000 patients in 34 European countries), University Hospital Ghent.

2014-ongoing: **Faculty council member**, Faculty of Medicine and Health Sciences.

2016-ongoing: replacement **member Research Council**.

2017-ongoing: **member commission of scientific research**

### **Commissions of Trust**

2013-ongoing: **Belgian Higher Health Council**, Scientific Advisory Board on HIV-1 topics

2014-ongoing: **King Baudouin Foundation**: Scientific committee member.

**Memberships of Scientific Societies:** 2009- ongoing: BREACH (Belgian network on HIV-1 research): founding member and scientific committee member. 2009-ongoing: ESAR (European Society of Antiviral Resistance), founded in Utrecht, I'm the Belgian Representative.

**Reviewer Activity:** Ad-hoc **reviewer** for Journal of Virology, AIDS, Retrovirology, Journal of Antimicrobial Chemotherapy, International Journal of AIDS, J. Exp Medicine...

2012- ongoing: Reviewer **Spanish Clinical Research Network**, Spain.

2013-ongoing: **Reviewing of Grants**: European selection committee: partnering for cure initiative, BMS Europe. 2012-ongoing: International Aids Society: reviewer of abstracts for the annual congress.

2013-ongoing: ECCMID (European Congress on Clinical Microbiology and Infectious Diseases): **reviewer of abstracts for the annual congress**.

2014-ongoing: **Editorial board**: Journal of viral eradication.

### **Overall publication track-record**

I have a total of >130 **authorships** in international peer review journals. My total number of times cited from the Web of Science is currently **1803**. The number of citations of the ten most cited articles is 1042. Mean impact factor of the articles of the last five years is 4.200. My h-index is **22**

**New research financing as well as current and recently concluded research financing (projects, grants and equipment) since January 2013**

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	KBS
Start and end date	1/10/2011-30/09/2014
Budget	100.000€ (UGent/UZGent)
Title	Evaluation of the viral reservoir in patient on ART
Researchers	/

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	Bill and Melinda Gates Foundation
Start and end date	1/01/2011-01/12/2014
Budget	100.000\$ (UGent/UZGent)
Title	Transcriptome analysis in a primary HIV latency model
Researchers	/

Promoter	<b>Linus Vandekerckhove, Sabine Kinloch</b>
Funding agency	American Foundation for Aids Research
Start and end date	1/04/2011-30/09/2015
Budget	300.000\$ (250.000\$ for UGent/UZGent)
Title	HIV DNA analysis in patients starting ART very early
Researchers	/

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	KBS
Start and end date	1/01/2015-31/12/2015
Budget	€40.000 (UGent/UZGent)
Title	Integration site analysis in patients on ART
Researchers	/

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	IWT (PhD mandate)
Start and end date	01/01/2012-31/12/2015
Person months	48 person months and bench fee (3.718,44 Euro yearly)
Title	HIV DNA as an important marker to distinguish different patient cohorts
Researchers	Eva Malatinkova

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	IWT (PhD mandate)

Start and end date	01/10/2011-31/09/2015
Person months	48 person months and bench fee (3.718,44 Euro yearly)
Title	HIV latency models
Researchers	Pawel Bonczkowski

Promoter	<b>Linos Vandekerckhove</b>
Funding agency	UGent startersgrant
Start and end date	01/04/2012-31/03/2016
Person months	1 FTE PhD student 4 jaar
Title	HIV RNA based assays to study the HIV reservoir
Researchers	Maja Kiselinova

Promoter	<b>Linos Vandekerckhove</b>
Funding agency	UGent
Start and end date	01/09/2012-31/08/2018
Person months	1 FTE PhD student 6 jaar
Title	The HIV transcriptome analysis based new targets for HIV latency
Researchers	Wim Trypsteen

Promoters and copromoters	De Baere Elfride, Coucke Paul, Vandesompele Jo, De Sutter Petra, <b>Vandekerckhove Linos</b> , Deforce E Dieter, Van Soom Ann, Peelman Luc, De Meyer Tim, Flamez Daisy, Bekaert Sofie, Messens Kathy
Funding agency	Herculus type II aanvraag
Start and end date	2013
Budget	€ 800.000
Title	HiSeq 2500: high-throughput next-generation sequencer for ultrafast and cheap decoding of whole exomes, genomes, transcriptomes, epigenomes and viromes.

Promoter	<b>Linos Vandekerckhove</b>
Funding agency	IWT (PhD mandate)
Start and end date	1/01/2016-31/12/2020
Person months	48 person months and bench fee (3.718,44 Euro yearly)
Title	HIV DNA as a new marker in HIV diagnostics
Researchers	Sofie Rutsaert

Promoter	<b>Linos Vandekerckhove</b>
Financierende instantie / Funding agency	IWT (PhD mandate)
Start and end date	1/01/2016-31/12/2020
Person months	48 person months and bench fee (3.718,44

	Euro yearly)
Title	The role van long non coding RNA's in HIV mediated apoptosis
Researchers	Clarissa Van Hecke

Promoter 2° promotor	Guido Vanham (ITG, Antwerp) <b>Linus Vandekerckhove</b>
Financierende instantie / Funding agency	IWT
Start and end date	1/01/2015-31/12/2019
Person months	48 person months and bench fee (3.718,44 Euro yearly)
Title	Viral outgrowth and inhibition assays for the monitoring of HIV latency
Researchers I	Pieter Pannus

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	BMS
Start and end date	1/10/2014-30/09/2016
Person months	€ 100.000 UGent
Title	Long non-coding RNAs functioning during HIV latency development
Researchers	/

Promoters and copromoters	<b>Vandekerckhove L</b> , Meuleman P, Verhasselt B, Van Vlierberghe P, Vemaelen K, De Spiegelaere W
Funding agency	UGent, BOF, Basisuitrusting
Start and end date	2015
Budget	€ 120.000
Title	Automatische bench-top cell sorter met biosafety hood voor gebruik in een biosafety level 3 faciliteit
Researchers	/

Promoters and copromoters	Eric Florence, <b>Linus Vandekerckhove</b> , Sabine Allard, Stephane De Wit, Guido Van Ham
Funding agency	IWT-TBM
Start and end date	11/2014-10/2018
Budget	€ 977.462, - (€361380 voor UGent/UZGent)
Title	Analytical treatment interruption in HIV positive patients with low viral reservoirs to evaluate the potential of a functional cure
Researchers	/

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	FWO
Start and end date	1/10/2015-30/09/2016

Person months	1 postdoc FTE 3 jaar (1x verlengbaar)
Title	Long non-coding RNAs functioning in HIV infection and latency development
Researchers	Ward De Spiegelaere

Promoter	Zeger Debyser, <b>Linus Vandekerckhove</b> , Renate Konig
Funding agency	HIV Era: IWT
Start and end date	1/10/2014-30/09/2016
Budget	€ 500.000, - (€ 250.000 voor UGent/UZGent)
Title	Exploring the molecular mechanisms of HIV latency
Researchers	/

Promoter	<b>Linus Vandekerckhove</b>
Funding agency	Gilead Sciences
Start and end date	1/01/2015-30/12/2015
Person months	€ 15.000
Title	Comparison of different HIV integration site analysis platforms
Researchers	/

Promoters and copromoters	Ole Schmelz Sogaard, Mathias Lichterfeld, Galit Alter, <b>Linus Vandekerckhove</b>
Funding agency	American Foundation for AIDS Research (amfAR)
Start and end date	01/01/2015-30/12/2016
Budget and/or person months	\$ 300.000 - (€ 30.000 for UGent/UZGent)
Title	Exploring the mechanisms for HIV persistence and the potential for HIV eradication using a TLR9 antagonist
Researchers	/

Promoters and copromoters	Javier Martinez Picado, <b>Linus Vandekerckhove</b>
Funding agency	ViiV healthcare
Start and end date	01/01/2015-30/12/2016
Budget and/or person months	€ 450.000 - (€ 130.000 for UGent/UZGent)
Title	Evaluation of the HIV reservoir in patients switching from a PI towards an integrase based regimen
Researchers	/

Promoters and copromoters	<b>Linus Vandekerckhove</b>
Funding agency	Merck
Start and end date	01/01/2015-30/12/2018
Budget and/or person months	€ 320.000 for UGent/UZGent
Title	HIV STAR study: evaluation the HIV sequences after structured treatment

	interruption and in depth sampling
Researchers	Marie-Angélique De Scheerder

Promoters and copromoters	<b>Linos Vandekerckhove</b>
Funding agency	BOF
Start and end date	01/10/2016-30/09/2017
Budget and/or person months	€ 220.000
Title	Evaluation of CMV driven clonal proliferation in patients on suppressive ART
Researchers	Eva Malatinkova

Promoters and copromoters	<b>Linos Vandekerckhove</b>
Funding agency	J&J
Start and end date	01/01/2017-31/12/2017
Budget and/or person months	€ 92.000
Title	HIV reservoir size as a predictor for virological failure in patients on chronic ART
Researchers	Sofie Rutsaert

Promoters and copromoters	<b>Linos Vandekerckhove</b>
Funding agency	Abivax
Start and end date	01/10/2016-30/06/2017
Budget and/or person months	€ 65.000
Title	Evaluation of the administration of ABX464 in patients on PI monotherapy
Researchers	Sofie Rutsaert

Promoters and copromoters	<b>Linos Vandekerckhove</b>
Funding agency	BOF
Start and end date	01/10/2016-01/09/2020
Budget and/or person months	€ 180.000
Title	CAR-T cells as a new tool to eradicate the HIV viral reservoir
Researchers	Jon Huyghe

Promoters and copromoters	<b>Linos Vandekerckhove</b> , Lisa Frenkel, James Mullins, Rafick Pierre Sékaly, Nicole Frahm, Oleg Denisenko
Funding agency	NIH
Start and end date	07/08/2017-31/07/2022
Budget and/or person months	\$ 776.759
Title	Defining HIV reservoirs that rebound following suspension of ART
Researchers	/

Promoters and copromoters	<b>Linos Vandekerckhove</b> , Eva Malatinkova
Funding agency	BOF
Start and end date	01/01/2018-31/12/2021
Budget and/or person months	€ 200.000

Title	Dissection of the HIV reservoir in acutely infected patients treated immediately
Researchers	/

Promoters and copromoters	<b>Linus Vandekerckhove</b>
Funding agency	FWO
Start and end date	01/01/2018-31/12/2021
Budget and/or person months	48 person months and bench fee (3.718,44 Euro yearly)
Title	Development of novel assays to characterize the size and dynamics of the HIV-1 viral reservoir
Researchers	Basiel Cole

Promoters and copromoters	<b>Linus Vandekerckhove</b>
Funding agency	ViiV healthcare
Start and end date	01/01/2017-30/12/2021
Budget and/or person months	€ 320.000
Title	Evaluation of the HIV reservoir in acute seroconverters: clinical sample collection
Researchers	/

Promoters and copromoters	<b>Linus Vandekerckhove</b>
Funding agency	BOF 2-4j Project
Start and end date	01/01/2017-30/12/2021
Budget and/or person months	€ 200.000
Title	Evaluation of the HIV reservoir acute seroconverters: in depth scientific analysis
Researchers	/



## Publications

1. Rutsaert S, Bosman K, Trypsteen W, Nijhuis M, Vandekerckhove L. Digital PCR as a tool to measure HIV persistence. *Retrovirology*. 2018 Jan 30. Vol 15.  
IF= 3.867  
Ranking: 11/35  
Q2
2. Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. *Lancet HIV*. 2018 Jan 15.  
IF=9.842  
Ranking= 2/84  
Q1
3. Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziolosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholz L, Sedláček D, Mozer-Lisewska I, Lundgren JD; EuroSIDA Study. Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? *AIDS*. 2018 Jan 14. Vol 32, issue 2 [205-215].  
IF= 5.019  
Ranking: 10/84  
Q1
4. Fun A, Leitner T, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Hoepelman AIM, Gisolf EH, Schipper PJ, Wensing AMJ, Nijhuis M. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. *Retrovirology*. 2018 Jan 1. Vol 15.  
IF= 3.867  
Ranking: 11/35  
Q2
5. Cahn, P; Kaplan, R; Sax, PE; Squires, K; Molina, JM; Avihingsanon, A; Ratanasuwan, W; Rojas, E; Rassool, M; Bloch, M; Vandekerckhove, L; Ruane, P; Yazdanpanah, Y; Katlama, C; Xu, X; Rodgers, A; East, L; Wenning, L; Rawlins, S; Homony, B; Sklar, P; Nguyen, BY; Leavitt, R; Teppler, H. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. *Lancet HIV*. 2017 Nov. Vol. 4 [11]  
IF=9.842  
Ranking= 2/84  
Q1
6. Line Vibholm, Mariane H Schleimann, Jesper F Højten, Thomas Benfield, Rasmus Offersen, Katrine Rasmussen, Rikke Olesen, Anders Dige, Jørgen Agnholt, Judith Grau, Maria Buzon, Burghardt Wittig, Mathias Lichterfeld, Andreas Munk Petersen, Xutao Deng, Mohammed Abdel-Mohsen, Satish K Pillai, Sofie Rutsaert, Wim Trypsteen, Ward De Spiegelaere, Linos Vandekerckhove, Lars Østergaard, Thomas A Rasmussen, Paul W Denton, Martin Tolstrup and Ole S Søgaard. Short-course TLR9 agonist treatment impacts innate immunity and plasma viremia in individuals with HIV infection. *Clinical Infectious Diseases*. Mar 2017.  
IF= 8.736  
Ranking: 2/83  
Q1

7. Symons J, Chopra A, Malatinkova E, De Spiegelaere W, Leary S, Cooper D, Abana CO, Rhodes A, Rezaei SD, Vandekerckhove L, Mallal S, Lewin SR, Cameron PU. HIV integration sites in latently infected cell lines: evidence of ongoing replication. *Retrovirology*. Mar 2017  

IF= 5.228  
Ranking: 7/63  
Q1
8. Bonczkowski P, De Scheerder MA, Malatinkova E, Borch A, Melkova Z, Koenig R, De Spiegelaere W, Vandekerckhove L. Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models. *Scientific Reports*. Dec 2016.  

IF= 5.228  
Ranking: 7/63  
Q1
9. Baeyens A, Naessens E, Van Nuffel A, Weening KE, Reilly AM, Claeys E, Trypsteen W, Vandekerckhove L2, Eyckerman S, Gevaert K, Verhasselt. HIV-1 Vpr N-terminal tagging affects alternative splicing of the viral genome. *Scientific Reports*. Oct 2016.  

IF= 5.228  
Ranking: 7/63  
Q1
10. Trypsteen W, Mohammadi P, Van Hecke C, Mestdagh P, Lefever S, Saeys Y, De Bleser P, Vandesompele J, Ciuffi A, Vandekerckhove L, De Spiegelaere W. Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay. *Scientific Reports*. Oct 2016.  

IF= 5.228  
Ranking: 7/63  
Q1
11. Vynck M, Trypsteen W, Thas O, Vandekerckhove L, De Spiegelaere W. The Future of Digital Polymerase Chain Reaction in Virology. *Molecular diagnosis & therapy*. Oct 2016  

IF=2.602  
Ranking: 77/166  
Q2
12. Lazarus JV, Laut KG, Safreed-Harmon K, Peters L, Johnson M, Fatkenheuer G, Khromova I, Vandekerckhove L, Maciejewska K, Radoi R, Ridolfo AL, Mocroft A. Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. *BMC infectious diseases*. 20 Jul 2016  

IF= 2.690  
Ranking:33/83  
Q2
13. Kiselina M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. *Plos Pathogens*. Mar 2016.  

IF= 7.003  
Ranking: 12/123  
Q1
14. Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D, Deblonde J, Delforge ML, Fransen K, Goffard JC, Legrand JC, Moutschen M, Pierard D, Ruelle J, Vaira D, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C. Late presentation to HIV testing is overestimated when based on the consensus definition. *HIV medicine*. Mar 2016.  

IF= 3.341  
Ranking: 23/83  
Q2

15. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V. Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. *Aids research and human retroviruses*. Feb 2016.
- IF= 1.949  
Ranking:56/83  
Q3
16. Vancoillie L, Mortier V, Demecheleer E, Schauvliege M, Vandekerckhove L, Vogelaers D, Verhofstede C. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. *Antiretroviral therapy*. 2015.
17. Malatinkova E, De Spiegelaere W, Bonczkowski P, Kiselina M, Vervisch K, Trypsteen W, Johnson M, Verhofstede C, de Looze D, Murray C, Kinloch-de Loes S, Vandekerckhove L. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. *Elife*. 2015 Oct 6.
- IF= 8.282  
Ranking: 4/86  
Q1
18. Bosman KJ, Nijhuis M, van Ham PM, Wensing AMJ, Vervisch K, Vandekerckhove L, De Spiegelaere W. Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir. *Scientific Reports UK*. SEP 9 2015.
- IF= 5.228  
Ranking: 7/63  
Q1
19. Sun H, Kim D, Li X, Kiselina M, Ouyang Z, Vandekerckhove L, Shang H, Rosenberg ES, Yu XG, Lichterfeld M. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. *J Virol*. 2015. Sep 2.
- IF= 4.606  
Ranking: 5/33  
Q1
20. Kiselina M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. *J Antimicrob Chemother*. 2015 Aug 31.
- IF= 4.919  
Ranking: 19/123  
Q1
21. Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D, Deblonde J, Delforge ML, Fransen K, Goffard JC, Legrand JC, Moutschen M, Piérard D, Ruelle J, Vaira D, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C; Belgian Research AIDS & HIV Consortium (BREACH). Late presentation to HIV testing is overestimated when based on the consensus definition. *HIV Med*. 2015 Jul 28.
- IF= 3.341  
Ranking: 23/83  
Q2
22. Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A; EuroSIDA in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA group. HIV resistance testing and detected drug resistance in Europe. *AIDS*. 2015 Jul 17.
- IF= 4.407

Ranking: 37/151  
Q1

23. Malatinkova E, De Spiegelaere W, Bonczkowski P, Kiselina M, Vervisch K, Trypsteen W, Johnson M, Verhofstede C, de Looze D, Murray C, Loes SKD, Vandekerckhove L. Long-term early antiretroviral therapy limits the HIV-1 reservoir size as compared to later treatment initiation but not to levels found in long-term non-progressors. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. Jul 2015.

IF= 6.256  
Ranking: 22/151  
Q1

24. Insight START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Linos Vandekerckhove is part of the INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

IF= 59.558  
Ranking: 1/155  
Q1

25. Trypsteen W, Vynck M, De Neve J, Bonczkowski P, Kiselina M, Malatinkova E, Vervisch K, Thas O, Vandekerckhove L, De Spiegelaere W. ddpcRquant: threshold determination for single channel droplet digital PCR experiments. ANALYTICAL AND BIOANALYTICAL CHEMISTRY. Jul 2015.

IF= 3.125  
Ranking: 25/77  
Q2

26. Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM; SPREAD programme. Linos Vandekerckhove is part of the SPREAD Programme. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. Jul 17.

IF= 4.919  
Ranking: 19/123  
Q1

27. Trypsteen W, De Neve J, Bosman K, Nijhuis M, Thas O, Vandekerckhove L, De Spiegelaere W. Robust regression methods for real-time polymerase chain reaction. ANALYTICAL BIOCHEMISTRY. ANAL BIOCHEM JUL 1 2015.

IF= 2.243  
Ranking: 32/75  
Q2

28. Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselina M, Pollakis G, Beloukas A, Vandekerckhove L, Strain M, Richman D, Phillips A, Geretti AM; ERAS Study Group. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ. Ebiomedicine Jul 2015.

IF= -  
Ranking: -

29. Gobin V, De Bock M, Broeckx BJG, Kiselina M, De Spiegelaere W, Vandekerckhove L, Van Steendam K, Leybaert L, Deforce D. Fluoxetine suppresses calcium signaling in

human T lymphocytes through depletion of intracellular calcium stores. CELL CALCIUM.  
jun 2015.

IF= 2.909  
Ranking: 102/187  
Q3

30. Swartz JE, Vandekerckhove L, Ammerlaan H, de Vries AC, Begovac J, Bierman WFW, Boucher CAB, van der Ende ME, Grossman Z, Kaiser R, Levy I, Mudrikova T, Paredes R, Perez-Bercoff D, Pronk M, Richter C, Schmit JC, Vercauteren J, Zazzi M, Lepej SZ, De Luca A, Wensing AMJ. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. Jun 2015.

IF= 4.919  
Ranking: 19/123  
Q1

31. Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA group. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015 Jun 19.

IF= 4.407  
Ranking: 37/151  
Q1

32. Vancoillie L, Mortier V, Demecheleer E, Schauvliege M, Vandekerckhove L, Vogelaers D, Verhofstede C. Drug resistance is rarely the cause or consequence of long-term persistent low-level viremia in HIV-1-infected patients on ART. Antivir Ther. 2015 May 6.

IF= 2.916  
Ranking: 15/33  
Q2

33. Kinloch S, Johnson M, Yang H, Dorrell L, Vandekerckhove L, Malatinkova E, De Spiegelaere W, Webster D. Aviremia 10-year post-ART discontinuation initiated at seroconversion. HIV MEDICINE. Apr 2015.

IF= 3.341  
Ranking: 23/83  
Q2

34. De Spiegelaere W, Philippé J, Vervisch K, Verhofstede C, Malatinkova E, Kiselina M, Trypsteen W, Bonczkowski P, Vogelaers D, Callens S, Ruelle J, Kabeya K, De Wit S, Van Acker P, Van Sandt V, Emonds MP, Coucke P, Sermijn E, Vandekerckhove L. Comparison of Methods for In-House Screening of HLA-B\*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care. PLoS One. 2015 Apr.

IF= 3.057  
Ranking: 11/63  
Q1

35. Ruggiero A, King S, Pollakis G, Beloukas A, Geretti AM, Vandekerckhove L, Kiselina M, De Spiegelaere W, Cozzi-Lepri A, Phillips A. The burden of integrated HIV-1 DNA during suppressive ART is associated with levels of activated (HLA-DR+) CD8 T cells. HIV MEDICINE. Apr 2015.

IF= 3.341  
Ranking: 23/83  
Q2

36. Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Linos Vandekerckhove is part of the D:A:D study group. Cancer risk and use of protease

inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. *J Acquir Immune Defic Syndr*. 2015 Apr 15.

IF= 3.586  
Ranking: 22/114  
Q1

37. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Linos Vandekerckhove is part of the INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. *HIV Med*. 2015 Apr;16.

IF= 3.341  
Ranking: 23/83  
Q2

38. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Linos Vandekerckhove is part of the D:A:D study group. Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med*. 2015 Mar.

IF= 13.585  
Ranking: 7/155  
Quartile: Q1

39. Swartz JE, Vandekerckhove L, Ammerlaan H, de Vries AC, Begovac J, Bierman WF, Boucher CA, van der Ende ME, Grossman Z, Kaiser R, Levy I, Mudrikova T, Paredes R, Perez-Bercoff D, Pronk M, Richter C, Schmit JC, Vercauteren J, Zazzi M, Židovec Lepej S(4), De Luca A, Wensing AM; on behalf of the European Society for translational Antiviral Research (ESAR). Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. *J Antimicrob Chemother*. 2015 Mar 3.

IF= 4.919  
Ranking: 19/123  
Q1

40. Malatinkova E, Kiselinova M, Bonczkowski P, Trypsteen W, Messiaen P, Vermeire J, Verhasselt B, Vervisch K, Vandekerckhove L, De Spiegelaere W. Accurate Quantification of Episomal HIV-1 Two-Long Terminal Repeat Circles by Use of Optimized DNA Isolation and Droplet Digital PCR. *Journal of clinical microbiology*. 2015 Feb.

IF= 3.631  
Ranking: 36/123  
Q2

41. W. De Spiegelaere, J. Dern-Wiehloch, R. Weigel, V. Schumacher, H. Schorle, D. Nettersheim, M. Bergmann, R. Brehm, S. Kliesch, L. Vandekerckhove, C. Fink. Reference gene validation for RT-qPCR, a note on different available software packages *Plos One*.

IF= 3.057  
Ranking: 11/63  
Q1

42. Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, Mocroft A; EuroSIDA in EuroCOORD. Linos Vandekerckhove is part of the EuroSida group. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. *AIDS*. 2014 Nov 13.

IF= 5.554  
Ranking: 5/33  
Q1

43. Kiselinova M, Anna M, Malatinkova E, Vervish K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L. The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART. *J Int AIDS Soc.* 2014 Nov 2.  
 IF= 5.090  
 Ranking: 25/148  
 Q1
44. Bourguignon P, Clément F, Renaud F, Le Bras V, Koutsoukos M, Burny W, Moris P, Lorin C, Collard A, Leroux-Roels G, Roman F, Janssens M, Vandekerckhove L. Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients. *J Immunol Methods.* 2014 Dec.  
 IF= 1.820  
 Ranking: 52/79  
 Q3
45. Bonczkowski P, De Spiegelaere W, Bosque A, White CH, Van Nuffel A, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk CH, Planelles V, Vandekerckhove L. Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. *Retrovirology.* 2014 Aug 21.  
 IF= 4.185  
 Ranking: 8/33  
 Q1
46. Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Linos Vandekerckhove is part of the NEAT study group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. *Lancet.* 2014 Nov 29.  
 IF= 45.217  
 Ranking: 2/154  
 Q1
47. Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Giskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme. Linos Vandekerckhove is part of the SPREAD Programme. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. *BMC Infect Dis.* 2014 Jul 21.  
 IF= 2.613  
 Ranking: 39/78  
 Q3
48. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Linos Vandekerckhove is part of the D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet.* 2014 Jul 19.  
 IF= 45.217  
 Ranking: 2/154  
 Q1

49. Buyle FM, Wallaert M, Beck N, Boelens J, Callens S, Claeys G, Deryckere S, Haegeman E, Leroux-Roels I, Sermijn E, Steel E, Robays H, Vandekerckhove L, Vermis K, Vogelaers D. Implementation of a multidisciplinary infectious diseases team in a tertiary hospital within an Antimicrobial Stewardship Program. *Acta Clin Belg.* 2014.

IF= 0.518  
Ranking: 125/154  
Q4

50. Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA group. Deteriorating renal function and clinical outcomes in HIV-positive persons. *AIDS.* 2014 Mar 13.

IF= 5.554  
Ranking: 5/33  
Q1

51. Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA group. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. *Infection.* 2014 Aug.

IF= 2.618  
Ranking: 38/78  
Q2

52. Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Linos Vandekerckhove is part of the D:A:D Study Group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. *HIV Med.* 2014 Nov;15.

IF= 3.988  
Ranking: 18/78  
Q1

53. Symons J, Vandekerckhove L, Hütter G, Wensing AM, van Ham PM, Deeks SG, Nijhuis M. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. *Clin Infect Dis.* 2014 Aug 15.

IF= 8.886  
Ranking: 9/119  
Q1

54. Frenzt D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Wensing A; SPREAD Programme. Linos Vandekerckhove is part of the SPREAD Programme. Patterns of transmitted HIV drug resistance in Europe vary by risk group. *PLoS One.* 2014 Apr 10.

IF= 3.234  
Ranking: 9/57  
Q1

55. Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Linos Vandekerckhove is part of the D:A:D Study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. *BMC Nephrol.* 2014 Mar 25.

IF= 1.690  
Ranking: 43/78



56. De Spiegelaere W, Malatinkova E, Lynch L, Van Nieuwerburgh F, Messiaen P, O'Doherty U, Vandekerckhove L. Quantification of integrated HIV DNA by repetitive-sampling Alu-HIV PCR on the basis of poisson statistics. *Clin Chem*. 2014 Jun.
- IF= 7.911  
Ranking: 1/30  
Q1
57. Kiselina M, De Spiegelaere W, Verhofstede C, Callens SF, Vandekerckhove L. Antiretrovirals for HIV prevention: when should they be recommended? *Expert Rev Anti Infect Ther*. 2014 Apr;12.
- IF= 3.461  
Ranking: 62/255  
Q1
58. Temmerman S, Vandekerckhove L, Sermijn E, Vogelaers D, Claeys G, Vaneechoutte M, Cools P, Callens S Disseminated infection with *Mycobacterium tuberculosis* in a male immunocompromised patient. *J Clin Microbiol*. 2014 Feb 12.
- IF= 3.993  
Ranking: 26/119  
Q1
59. Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. *PLoS One*. 2014 Jan 31.
- IF= 3.234  
Ranking: 9/57  
Q1
60. Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP; EuroSIDA in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA group. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. *J Infect Dis*. 2014 Jul 15.
- IF= 5.997  
Ranking: 18/148  
Q1
61. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirde M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. *J Clin Microbiol*. 2014 Feb.
- IF= 3.993  
Ranking: 26/119  
Q1
62. Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. *AIDS*. 2014 Feb 20.
- IF= 5.554  
Ranking: 5/33  
Q1

63. Kiselinova M, Pasternak AO, De Spiegelaere W, Vogelaers D, Berkhout B, Vandekerckhove L. Comparison of Droplet Digital PCR and Seminested Real-Time PCR for Quantification of Cell-Associated HIV-1 RNA. *PLoS One*. 2014 Jan 21.  
IF= 3.234  
Ranking: 9/57  
Q1
64. Vancoillie L, Demecheleer E, Callens S, Vogelaers D, Vandekerckhove L, Mortier V, Verhofstede C. Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. *J Antimicrob Chemother*. 2014 Apr.  
IF= 5.313  
Ranking: 17/119  
Q1
65. Mortier V, Dauwe K, Vancoillie L, Staelens D, Van Wanzelee F, Vogelaers D, Vandekerckhove L, Chalmet K, Verhofstede C. Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients. *PLoS One*. 2013 Nov 7.  
IF= 3.534  
Ranking: 8/55  
Q1
66. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Linos Vandekerckhove is part of the SINGLE Investigators group. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013 Nov 7.  
IF= 54.420  
Ranking: 1/156  
Q1
67. Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Linos Vandekerckhove is part of the D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. *BMC Infect Dis*. 2013 Oct 9.  
IF= 2.561  
Ranking: 35/72  
Q2
68. Sermijn E, Strobbe T, Vandekerckhove L, Libbrecht L, Colle I, Schoonjans R, Vogelaers D. Calciphylaxis: a rare complication in alcoholic liver disease. *Acta Clin Belg*. 2013 Mar-Apr.  
IF= 0.713  
Ranking: 109/156  
Q3
69. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. *HIV Med*. 2013 Nov.  
IF= 3.454  
Ranking: 20/72  
Q2
70. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Linos Vandekerckhove is part of the D:A:D Study Group.

Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013 Nov 13.

IF= 6.102  
Ranking: 3/33  
Q1

71. Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, Leroux-Roels G Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine. 2013 Aug 12.

IF= 3.485  
Ranking: 53/144  
Q1

72. Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA Study Group. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS. 2013 Mar 27.

IF= 6.102  
Ranking: 3/33  
Quartile Q1

73. De Spiegelaere W, Malatinkova E, Kiselina M, Bonczkowski P, Verhofstede C, Vogelaers D, Vandekerckhove L. Touchdown digital polymerase chain reaction for quantification of highly conserved sequences in the HIV-1 genome. Anal Biochem. 2013 Aug 15.

IF= 2.305  
Ranking: 32/76  
Q2

74. Dekeyzer S, Moerman F, Callens S, Vandekerckhove L. Cutaneous metastatic tuberculous abscess in a patient with cervico-mediastinal lymphatic tuberculosis. Acta Clin Belg. 2013 Jan-Feb.

IF= 0.713  
Ranking: 109/156  
Q3

75. Frenzt D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme. Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology. 2013 Apr 3.

IF= 4.767  
Ranking: 6/33  
Q1

76. Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. 2013 Jul;14.

IF= 3.454  
Ranking: 20/72  
Q2

77. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Linos Vandekerckhove is part of the D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. *J Infect Dis.* 2013 May 1.
- IF= 5.778,  
Ranking: 20/144  
Quartile: Q1
78. Arribas JR, Doroana M, Turner D, Vandekerckhove L, Streinu-Cercel A. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. *AIDS Res Ther.* 2013 Jan 24.
- IF= 1.841  
Ranking: 54/72  
Q4
79. Messiaen P, Wensing A, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. *Plos One* 2013.
- IF= 3.534  
Ranking: 8/55  
Q1
80. Messiaen P, De Spiegelaere W, Alcamí J, Vervisch K, Van Acker P, Verhasselt B, Meuwissen P, Calonge E, Gonzalez N, Gutierrez-Rodero F, Rodriguez-Martin C, Sermijn E, Poppe B, Vogelaers D, Verhofstede C, Vandekerckhove L. Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. *PLoS One* 2012.
- IF= 3.730  
Ranking: 7/56  
Q1
81. Symons, J, Deeks S, Hutter G, Wensing A, Martin J, van Ham P, Vandekerckhove L, and Nijhuis M. 2012. "The Cure of the 'Berlin Patient': Why Did Pre-existing X4-variants Not Emergence After Allogeneic CCR5-Delta 32 SCT?" In *Journal of the International Aids Society*, 2012.
- IF= 3.936  
Ranking: 17/69  
Q1
82. Van Beckhoven D, Buvé A, Ruelle J, Seyler L, Sasse A; Belgian HIV Cohort Study Group, Lacor P, Florence E, Van Wijngaerden E, Vandercam B, Goffard JC, Vogelaers D, Vandekerckhove L, Moutschen M, De Wit S, Gobau P, Van Ranst M, Liesnard C, Franssen K, Plum J, Pierard D, Gothot A, Van den Wijngaert S. A national cohort of HIV-infected patients in Belgium: design and main characteristics. *Acta Clin Belg.* 2012 Sep.
- IF= 0.589  
Ranking: 110/155  
Q3
83. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaud R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Linos Vandekerckhove is part of the ART-CC Group. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *Int J Epidemiol.* 2012 Dec.
- IF= 6.982  
Ranking: 3/161  
Q1

84. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Linos Vandekerckhove is part of the D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *J Int AIDS Soc.* 2012 Oct 10.
- IF= 3.936  
Ranking: 17/70  
Quartile: Q1
85. Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Linos Vandekerckhove is part of the EuroSIDA Group. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. *Antivir Ther.* 2012.
- IF= 3.073  
Ranking: 72/261  
Q2
86. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. *PLoS One.* 2012.
- IF= 3.730  
Ranking: 7/56  
Q1
87. Verhofstede C, Nijhuis M, Vandekerckhove L. Correlation of coreceptor usage and disease progression. *Curr Opin HIV AIDS* 2012.
- IF= 4.704  
Ranking: 9/70  
Q1
88. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group, Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. *AIDS.* 2012 Sep 24.
- IF= 6.407  
Ranking: 3/70  
Q1
89. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. Linos Vandekerckhove is part of the GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. *Lancet.* 2012 Jun 30.
- IF= 39.060  
Ranking: 2/155  
Q1
90. Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver L J, Vandekerckhove L. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naïve patients. *Virology* 2012.
- IF= 3.367  
Ranking: 9/34  
Q2

91. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, Vogelaers D, Vandekerckhove L, Plum J, Verhofstede C (2012) Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. *J Infect Dis* 2012.
- IF= 5.848  
Ranking: 5/70  
Q1
92. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. Linos Vandekerckhove is part of the EuroSIDA Group. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. *AIDS*. 2011 Nov 28.
- IF= 6,245  
Ranking: 5/32  
Q1
93. Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, van Ham P M, van Lelyveld S F, Stam A J, van Versendaal D, Nijhuis M, Wensing A M. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. *Clin Microbiol Infect* 2012.
- IF= 4,578  
Ranking: 11/70  
Q1
94. Paredes R, Puertas MC, Bannister W, Kistic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group. Linos Vandekerckhove is part of the EuroSIDA GroupA376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. *J Infect Dis*. 2011 Sep 1.
- IF= 6,410  
Ranking: 3/70  
Q1
95. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Linos Vandekerckhove is part of the EuroSIDA Group. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. *AIDS*. 2011 Jul 31.
- IF= 6,245  
Ranking: 5/32  
Q1
96. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. Linos Vandekerckhove is part of the EuroSIDA GroupVitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. *AIDS*. 2011 Jun 19.
- IF= 6,245  
Ranking: 5/32  
Q1
97. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti A M. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. *HIV Med* 2011.
- IF= 3,006  
Ranking: 28/70  
Q2
98. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; EuroSIDA Study Group. Linos Vandekerckhove is part of the EuroSIDA Group A standardized algorithm for determining the underlying

cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. *HIV Clin Trials*. 2011 Mar-Apr.

IF= 1,638  
Ranking: 52/70  
Q3

99. Vandekerckhove LP, Wensing A M, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti A M, Klimkait T, Korn K, Masquelier B, Perno C F, Schapiro J M, Soriano V, Sonnerborg A, Vandamme A M, Verhofstede C, Walter H, Zazzi M, Boucher C A, European Consensus Group on clinical management of tropism. European guidelines on the clinical management of HIV-1 tropism testing. *Lancet Infect Dis* 2011.

IF= 17,391  
Ranking: 1/70  
Q1

100. Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. Linos Vandekerckhove is part of the EuroSIDA Group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. *J Antimicrob Chemother*. 2011 Apr.

IF= 5.068  
Ranking: 7/70  
Q1

101. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. *HIV Medicine*. 2011 May

IF= 3.006  
Ranking: 17/58  
Q2

102. Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandembroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti A M, Stuyver L J (2011) Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. *J Antimicrob Chemother*. 2011.

IF= 5,068  
Ranking: 20/261  
Q1

103. Fun A, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Maarschalk-Ellerbroek LJ, Schipper PJ, Wensing AMJ, and Nijhuis M. "Selection of the Raltegravir Resistance Pathway Is Affected by the HIV-1 Population Size." In *Antiviral Therapy*, 2011.

IF= 3.161  
Ranking: 68/259  
Q2

104. Brusselaers N, Monstrey S, Snoeij T, Vandijck D, Lizy C, Hoste E, Lauwaert S, Colpaert K, Vandekerckhove L, Vogelaers D, Blot S. Morbidity and mortality of bloodstream infections in patients with severe burn injury. *American Journal of critical care*. 2010 Nov 1.

IF= 1.656  
Ranking: 17/23  
Q3

105. Guysens V, Vandekerckhove L, Colle I, De Rudder P, Blots S, Vogelaers D. Invasive infection with *Rhodococcus equi*--two case reports and review of literature. *Acta Clinica Belgica*. 2010 Jul-Aug.

IF=0.592  
Ranking: 105/153  
Q3

106. Chalmet K, Staelens D, Blot S, Dinakis S, Pelgrom J, Plum J, Vogelaers D, Vandekerckhove L, Verhofstede C. Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. *BMC infectious diseases*. 2010 Sep 7.

IF= 2.825  
Ranking: 27/58  
Q2

107. Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miró JM; EuroSIDA Investigators. Dialysis and renal transplantation in HIV-infected patients: a European survey. *JAIDS- J. Acquired immune deficiency syndrome*. 2010 Dec 15.

IF= 4.262  
Ranking: 27/134  
Q1

108. Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. *Aids Research and Therapy*. 2010.

IF= 1.780  
Ranking: 51/70  
Q3

109. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. *JAIDS- J. Acquired immune deficiency syndrome*. 2010 Oct.

IF= 4.262  
Ranking: 27/134  
Q1

110. Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil*. 2010 Oct.

IF= 2,164  
Ranking: 44/114  
Q2

111. De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, Van Vlierberghe H. Severe drug-induced liver injury associated with prolonged use of linezolid. *Journal of medical toxicology*. 2010 Sep.

112. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. *HIV Medicine*. 2010 Aug

IF= 1,714  
Ranking: 17/58  
Q2

113. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. *AIDS*. 2010 Jul

Q1



114. Delanghe JR, Philippé J, Moerman F, De Buyzere ML, Vynckier LL, Verstraete AG, Vogelaers DP, Vandekerckhove L. Impaired hemoglobin scavenging during an acute HIV-1 retroviral syndrome. *Clinica Chimica Acta*. 2010 Apr 2.  
IF= 2.389  
Ranking: 6/31  
Q1
115. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J; EuroSIDA. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. *Journal of antimicrobial chemotherapy*. 2010 Mar.  
IF= 4.659  
Ranking: 17/252  
Q1
116. Vandekerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. *Current opinion in investigational drugs*. 2010 Feb.  
IF= 2.531  
Ranking: 65/252  
Q2
117. Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. *AIDS*. 2010 Mar.  
Q1
118. Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS*. 2010 Jan.  
Q1
119. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. *AIDS*. 2009 Aug 24.  
IF= 4.909  
Ranking: 5/57  
Q1
120. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: perspectives for use in antiretroviral-naïve HIV-1-infected patients. *Journal of Antimicrobial Chemotherapy*. 2009 Jun.  
IF= 4.352  
Ranking: 7/57  
Q1
121. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. *J. Acquired immune deficiency syndrome*. 2009 Feb.  
IF=3.586  
Ranking: 7/36  
Q1
122. Vandijck DM, Blot SI, Vandekerckhove L, Vogelaers DP. Fluconazole exposure and selection for *Candida non-albicans*. *Anesthesia and Analgesia*. 2008 Dec.

IF= 2.590  
Ranking: 6/22  
Q2

123. Chalmet K, Van Wanseele F, Demecheleer E, Dauwe K, Pelgrom J, Van Der Gucht B, Vogelaers D, Plum J, Stuyver L, Vandekerckhove L, Verhofstede C. Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains. *Virology*. 2008 Sep.

IF= 3.539  
Ranking: 8/27  
Q2

124. Vandekerckhove L, Blot S, Vogelaers D. Abacavir hypersensitivity. *New England Journal of Medicine*. 2008 Jun.

IF= 60  
Q1

125. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: integration of a new antiretroviral drug class into clinical practice. *Journal of Antimicrobial Chemotherapy*. 2008 Jun.

IF= 4.328  
Ranking: 31/219  
Q1

126. Verhofstede C, Van Wanseele F, Van Der Gucht B, Pelgrom J, Vandekerckhove L, Plum J, Vogelaers D. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml. *Journal of Medical Virology*. 2007 Sep

IF= 2.831  
Ranking: 12/25  
Q2

127. De Rijck J, Vandekerckhove L, Christ F, Debyser Z. Lentiviral nuclear import: a complex interplay between virus and host. *Bioessays*. 2007 May.

IF= 5.402  
Ranking: 5/71  
Q1

128. Hombrouck A, De Rijck J, Hendrix J, Vandekerckhove L, Voet A, De Maeyer M, Witvrouw M, Engelborghs Y, Christ F, Gijsbers R, Debyser Z. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. *PLoS Pathogens*. 2007 Mar.

IF= 9.336  
Ranking: 1/23  
Q1

129. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, Vercammen J, Engelborghs Y, Christ F, Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. *Journal of virology*. 2006 Dec.

IF= 5.341  
Ranking: 3/23  
Q1

130. Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, Van den Haute C, Witvrouw M, Debyser Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. 2006 Feb.

IF= 5.341  
Ranking: 3/23

131. Van Maele B., Busschots K., Vandekerckhove L., Christ F., Debyser Z. Cellular co-factors of HIV-1 integration. Trends in Biochemical Sciences. 2006.

IF= 13.863  
Ranking: 7/262  
Q1

132. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J. Engelborghs Y., Christ F., Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. Journal of Virology. 2006.

IF= 5.341  
Ranking: 3/23  
Q1

133. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, Tempé D, Vandekerckhove L, Moisant F, Ben-Slama L, Witvrouw M, Christ F, Rain JC, Dargemont C, Debyser Z, Benarous R. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. Journal of biological chemistry. 2005 Jul.

IF= 5.854  
Ranking: 38/261  
Q1

